Food Allergy- Pipeline Insight, 2025

This “Food Allergy- Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Food Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Food Allergy: Understanding

Food Allergy: Overview

Food allergies are adverse health effects resulting from a specific immune response that occurs reproducibly on exposure to a given food. These immune responses can range from mild to severe, potentially affecting the skin, gastrointestinal tract, respiratory, and cardiovascular systems. Food allergies are distinct from food intolerances, which do not involve the immune system and are generally less severe. The prevalence of food allergies has been rising, especially in developed countries, with an estimated 5-8% of children and 1-2% of adults affected worldwide.

Symptoms of food allergies can vary greatly, ranging from mild to life-threatening. Common signs include hives, itching, or eczema; swelling of the lips, face, tongue, and throat; wheezing, nasal congestion, or trouble breathing; abdominal pain, diarrhea, nausea, or vomiting; and dizziness, lightheadedness, or fainting. In severe cases, a food allergy can trigger anaphylaxis, a sudden and severe reaction that can include difficulty breathing, a drop in blood pressure, and loss of consciousness, requiring immediate medical attention.

Food allergies can be categorized into three main types based on the immune mechanisms involved: IgE-mediated, non-IgE-mediated, and mixed IgE and non-IgE-mediated. IgE-mediated food allergies are the most common and occur when immunoglobulin E (IgE) antibodies react to specific food proteins. Non-IgE-mediated allergies involve other components of the immune system and tend to cause gastrointestinal symptoms. Mixed IgE and non-IgE-mediated allergies involve both types of immune responses and can cause a range of symptoms, including both immediate and delayed reactions.

The causes of food allergies are multifactorial, involving genetic and environmental factors. Family history of allergies, asthma, or eczema increases the risk of developing food allergies. Early introduction of allergenic foods, hygiene hypothesis (suggesting that a lack of early childhood exposure to infectious agents, symbiotic microorganisms, and parasites increases susceptibility to allergic diseases), and vitamin D deficiency have been proposed as contributing factors. Common food allergens include milk, eggs, peanuts, tree nuts, fish, shellfish, soy, and wheat. Diagnosing food allergies typically involves a combination of medical history, dietary review, skin prick tests, blood tests for specific IgE antibodies, and oral food challenges under medical supervision. Management and treatment focus on avoiding the allergenic food, educating patients on reading food labels, and recognizing and managing symptoms of allergic reactions. In cases of severe allergies, patients are advised to carry an epinephrine auto-injector to treat anaphylaxis. Emerging treatments, such as oral immunotherapy, aim to desensitize patients to allergens, but these are still under research and not widely available. In summary, food allergies are a significant health concern due to their potential severity and rising prevalence. Understanding the signs, categories, causes, and appropriate diagnosis and treatment methods is crucial for effective management and prevention of severe allergic reactions.

'Food Allergy- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Food Allergy pipeline landscape is provided which includes the disease overview and Food Allergy treatment guidelines. The assessment part of the report embraces, in depth Food Allergy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Food Allergy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Food Allergy R&D. The therapies under development are focused on novel approaches to treat/improve Food Allergy.

Food Allergy Emerging Drugs Chapters

This segment of the Food Allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Food Allergy Emerging Drugs

Viaskin Peanut: DBV Technologies

Viaskin Peanut (DBV712) is the novel product candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers biologically active compounds to the immune system through the skin. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. The Viaskin patch contains a deposit of dry allergen at its center that sits above the skin on a backing film. When the patch is applied to intact skin, a condensation chamber is formed between the allergen and the top layer of skin, the epidermis. Natural water loss from the skin accumulates within the condensation chamber, solubilizing the allergen. The drug is currently being investigated in the Preregistration stage of development for the treatment of peanut allergy.

PVX-108: Aravax

PVX108 is a next-generation, allergen-specific immunotherapy using peptides that represent critical fragments of peanut proteins to precisely target the T cells driving peanut allergy. Administered once per month, therapy is designed to precisely induce tolerance to peanut protein without the safety concerns constraining the use of the only registered therapy which uses natural extracts from peanuts. The presence of whole peanut allergens in those extracts exposes patients to significant risks of anaphylaxis. Previously, a randomized, double-blind, placebo-controlled Phase I trial in 66 peanut-allergic adults (AVX-001) showed no evidence of adverse events of clinical concern. Additionally, ex vivo studies providing a surrogate measure of safety (basophil activation) in 185 peanut-allergic blood donors confirmed a lack of basophil reactivity to PVX108 in contrast to peanut extract. These data demonstrate that PVX108 has a highly favourable safety profile for treatment of peanut allergic patients, including those with severe allergy. The drug is currently being investigated in the Phase II stage of development for the treatment of peanut allergy.

AIMab7195: Xencor

AIMab7195 is an anti-IgE monoclonal antibody with enhanced binding to the Fc gamma receptor IIb (FcγRIIb). IgE recognizes and interacts with allergens and, as a result, can activate immune cells, such as mast cells and basophils that drive an allergic response in patients. AIMab7195 is designed to clear IgE rapidly from circulation, to prevent the production of IgE by preventing the activation of IgE-positive B cells, and to block IgE from interacting with its receptor on immune cells. AIMab7195 has been evaluated in two Phase I studies that enrolled more than 100 healthy volunteers and patients with allergy and atopic disease. The drug is currently being investigated in the Phase I stage of development for the treatment of peanut allergy.

Food Allergy: Therapeutic Assessment

This segment of the report provides insights about the different Food Allergy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Food Allergy

There are approx. 25+ key companies which are developing the therapies for Food Allergy. The companies which have their Food Allergy drug candidates in the most advanced stage, i.e. Preregistration include, DBV Technologies.

Phases

The report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Food Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Food Allergy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Food Allergy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Food Allergy drugs.

Food Allergy Report Insights

• Food Allergy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Food Allergy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Food Allergy drugs?
• How many Food Allergy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Food Allergy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Food Allergy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Food Allergy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• DBV Technologies
• Aravax
• Xencor
• Novartis AG
• DBV Technologies
• Vedanta Biosciences
• Alladapt Immunotherapeutics
• Intrommune Therapeutics
• IgGenix
• Lapix Therapeutics
• Neovacs
• Inimmune

Key Products

• Viaskin Peanut
• PVX-108
• AIMab7195
• Ligelizumab
• DBV 135
• VE416
• ADP101
• INT301
• Research programme : antiallergy therapeutics
• Tim3/4 agonist therapeutics - LAPIX Therapeutics
• IL-4/IL-13 immonotherapy
• INI 2004

This product will be delivered within 1-3 business days.